Keith Bailey Email & Phone Number

United States

• Deliver mid/long-term brand expansion strategies for the atherosclerosis franchise
• Led Cardiovascular long-term portfolio strategy development team resulting in approved 20-year plan
• Led successful FDP evaluation and recommendation for CVOT supporting LEQVIO in primary prevention
• Established and led 5+ cross-functional sub-teams evaluating potential LCM opportunities
• Provided ad-interim global commercial leadership for pelacarsen (5 months)

East Hanover, New Jersey, United States

Provide global commercial leadership for the CRM Franchise developing therapy area strategy, preparing pipeline assets from proof of concept through end of Phase III, and evaluation of BD&L opportunities.

East Hanover

Development and execution of US pre-launch strategy and key tactics for assets within the cardiovascular, metabolic and renal portfolio.

Greater New York City Area

Specializing in Life Sciences and dedicated to providing best-in-class strategy and management consulting to our clients, empowering them to respond faster to changing market dynamics.Designing and implementing transformation strategies to achieve measurable results for our clients.

Florham Park, NJ

Led global commercial matrix team in preparation for launch of naldemedine, including global development of brand’s strategic elements. Recent highlights:» Identified and evaluated market expansion opportunities for naldemedine and ospemifene.» Developed global commercialization plan for naldemedine and created target product profile.» Selected and manage.

Directed international product manager and global cross-functional business and lifecycle team across all markets, including Roche/GSK alliance and Roche-only markets, for ongoing growth of late lifecycle drug Bonviva in its last three years of patent protection. Key highlights:» Drove market share gains and growth to $1B in sales per year for three.

Bonviva Headed development of 2009 global strategic plan for late lifecycle product in addition to competitive strategy in anticipation of Actonel OAM launch. Key highlights:» Drove identification of additional differentiators demonstrating long-term patient impact. MirceraLiaison between US and global teams for Mircera, driving development and execution.

» Key marketing leadership role in deal close with Japan Tobacco for their CETP inhibitor.» Created and presented business assessment for licensing opportunities leading to several deals.» Project leader for out-licensing of Rocaltrol in US market.

» Headed cross-functional task force to develop managed care action plan for Xenical. » Led feasibility assessment of improved fair balancing language for Xenical consumer advertising.» Managed marketing for development of weight management program for the VA.» Steered development and implementation of web-based physician locator for consumers.

Nutley, NJ

» Revamped marketing strategy for Xenical to strengthen brand performance.» Directed market analysis and launch plan development for Klonopin Wafers.

Nutley, NJ

» Oversaw market research, forecasting, and analysis for five brands.» Led market research in preparation for launch of Valcyte and two new indications of Tamiflu.

Nutley, NJ

» Devised and implemented market research plan for launch of Tamiflu with consumer/professional audiences.» Developed patient based forecast models for Tamiflu and Tasmar.» Designed and executed primary and secondary market research for several Roche brands.

Nutley, New Jersey, United States